Overcoming Hurdles to Optimal Care for Patients with NTM-LD

Activity Overview

In this activity, a panel of experts discuss current guidelines and best practices for the management of nontuberculous mycobacterial lung disease (NTM-LD), including treatment options for refractory disease and strategies for minimizing adverse effects of therapies. An experienced patient with NTM-LD shares her experiences with oral and inhaled therapies and how she overcame treatment challenges.

0.50 CE Credit(s)
Expires: August 16, 2022

Target Audience

This activity is intended for pulmonology, infectious disease, internal medicine clinicians, and other healthcare professionals involved in the treatment of patients with nontuberculous mycobacterial lung disease (NTM-LD).

Learning Objectives

Upon successful completion of this education activity, participants should be better able to:

  • Employ current data, guidelines, and best practices when managing individuals with nontuberculous mycobacterial lung disease (NTM-LD)
  • Apply strategies to maintain adherence and address treatment-related adverse effects in patients with NTM-LD

Activity Faculty


Patrick A. Flume, MD

Professor, Medicine and Pediatrics
Medical University of South Carolina
Charleston, SC


Doreen J. Addrizzo-Harris, MD

Professor of Medicine
Associate Director, Clinical and Academic Affairs
Director, NYU Bronchiectasis/NTM Program
NYU Grossman School of Medicine
New York, NY


Julie V. Philley, MD

Executive Vice President, Health Affairs
University of Texas Health Science Center at Tyler
Tyler, TX